甲泼尼龙作为取栓辅助治疗急性颅内颈内动脉闭塞性卒中:MARVEL随机临床试验的事后二次分析
本文为MARVEL随机双盲安慰剂对照试验的事后二次分析,纳入2022年2月9日至2023年6月30日中国82家卒中中心1680例大血管闭塞患者中579例颅内ICA闭塞者,比较静脉甲泼尼龙2 mg/kg/d(最大160 mg)连用3天+EVT与安慰剂+EVT。甲泼尼龙组90天独立步行(mRS 0-3)比例显著高于安慰剂组(53.2% vs 42.7%;校正RR 1.27,95%CI 1.07-1.52;P=0.007),症状性颅内出血(9.4% vs 15.5%;校正RR 0.55,95%CI 0.35-0.87;P=0.01)和去骨瓣减压率(5.6% vs 9.9%;校正RR 0.54,95%CI 0.30-0.98;P=0.04)均降低,90天死亡率无显著差异(32.4% vs 37.9%;校正RR 0.84,95%CI 0.67-1.05;P=0.13)。作者认为静脉甲泼尼龙作为EVT辅助治疗可能是有前景的治疗选择。
要点
- 颅内ICA闭塞取栓患者中,甲泼尼龙组90天独立步行(mRS 0-3)151/284(53.2%)vs 安慰剂组125/293(42.7%),校正RR 1.27(95%CI 1.07-1.52),P=0.007。
- 甲泼尼龙组症状性颅内出血26/277(9.4%)vs 安慰剂组45/290(15.5%),校正RR 0.55(95%CI 0.35-0.87),P=0.01。
- 甲泼尼龙组去骨瓣减压16/286(5.6%)vs 安慰剂组29/293(9.9%),校正RR 0.54(95%CI 0.30-0.98),P=0.04。
- 90天死亡率甲泼尼龙组92/284(32.4%)vs 安慰剂组111/239(37.9%),校正RR 0.84(95%CI 0.67-1.05),P=0.13,无显著差异。
- 方案为静脉甲泼尼龙2 mg/kg/d(最大剂量160 mg)连用3天+EVT,对照为安慰剂+EVT。
适用人群与场景
- MARVEL试验纳入的最后已知健康时间24小时内、颅内ICA、大脑中动脉第一段(M1)或第二段(M2)大血管闭塞患者;本分析仅取其中颅内ICA闭塞者579例。
- 本分析人群:中位年龄69.0岁(IQR 59.0-76.0岁),男性338例(58.4%);甲泼尼龙组286例,安慰剂组293例。
诊断标准与关键阈值
- 主要终点为90天独立步行,定义为改良Rankin量表(mRS,0分[无症状]至6分[死亡])评分0至3分。
- 安全性终点包括90天内死亡、48小时内症状性颅内出血(sICH)及EVT后为缓解中线移位和颅内压而行去骨瓣减压。
处置流程与药物剂量
- 甲泼尼龙组:静脉甲泼尼龙2 mg/kg/d(最大剂量160 mg)连用3天,联合EVT。
- 对照组:安慰剂联合EVT。
研究设计与关键结果
- 研究类型:MARVEL随机双盲安慰剂对照临床试验的事后二次分析;2022年2月9日至2023年6月30日在中国82家卒中中心开展,随访3个月;原试验纳入1680例,本分析纳入579例颅内ICA闭塞患者。
- 90天独立步行(mRS 0-3):甲泼尼龙组151/284(53.2%)vs 安慰剂组125/293(42.7%),校正RR 1.27(95%CI 1.07-1.52),P=0.007。
- 症状性颅内出血(48小时内):甲泼尼龙组26/277(9.4%)vs 安慰剂组45/290(15.5%),校正RR 0.55(95%CI 0.35-0.87),P=0.01。
- 去骨瓣减压:甲泼尼龙组16/286(5.6%)vs 安慰剂组29/293(9.9%),校正RR 0.54(95%CI 0.30-0.98),P=0.04。
- 90天死亡:甲泼尼龙组92/284(32.4%)vs 安慰剂组111/239(37.9%),校正RR 0.84(95%CI 0.67-1.05),P=0.13,无显著差异。
证据类型、等级与局限
- 证据类型:随机双盲安慰剂对照临床试验(MARVEL)的事后二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,静脉甲泼尼龙作为EVT辅助治疗可能是有前景的治疗选择,适用于颅内ICA闭塞的AIS取栓患者。
- 本分析显示甲泼尼龙与90天独立步行改善、sICH和去骨瓣减压率降低相关, mortality无显著差异。
指南或共识出处
- MARVEL随机临床试验(ChiCTR.org.cn Identifier: ChiCTR2100051729)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Patients with acute ischemic stroke (AIS) due to intracranial internal carotid artery (ICA) occlusion often have poor functional outcomes despite undergoing endovascular thrombectomy (EVT).
OBJECTIVE: To investigate the effectiveness and safety associated with intravenous methylprednisolone as adjunctive treatment to EVT for patients with AIS due to intracranial ICA occlusion.
DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the MARVEL randomized, double-blind, placebo-controlled clinical trial conducted from February 9, 2022, to June 30, 2023, at 82 stroke centers across China with a 3-month follow-up. The primary trial enrolled 1680 patients with large vessel occlusion within 24 hours from last known well time in the intracranial ICA, the first segment of the middle cerebral artery (M1), or the second segment of the middle cerebral artery (M2), of whom 579 patients had intracranial ICA occlusion.
INTERVENTION: Intravenous methylprednisolone, 2 mg/kg/d (maximum dose, 160 mg) for 3 days plus EVT vs placebo plus EVT.
MAIN OUTCOMES AND MEASURES: The primary outcome was independent ambulation at 90 days, defined as a score of 0 to 3 on the modified Rankin Scale (range, 0 [no symptoms] to 6 [death]). Safety outcomes included death within 90 days, symptomatic intracranial hemorrhage (sICH) within 48 hours, and decompressive hemicraniectomy to relieve midline-shift and intracranial pressure after EVT.
RESULTS: Among 579 patients (median age, 69.0 years [IQR, 59.0-76.0 years]; 338 men [58.4%]), there were 286 patients in the methylprednisolone group and 293 patients in the placebo group. The proportion of patients who achieved 90-day independent ambulation was significantly higher in the methylprednisolone group than in the placebo group (151 of 284 [53.2%] vs 125 of 293 [42.7%]; adjusted risk ratio [RR], 1.27 [95% CI, 1.07-1.52]; P = .007). The incidence of sICH was lower in the methylprednisolone group than in the placebo group (26 of 277 [9.4%] vs 45 of 290 [15.5%]; adjusted RR, 0.55 [95% CI, 0.35-0.87]; P = .01). The rate of decompressive hemicraniectomy was lower in the methylprednisolone group compared with the placebo group (16 of 286 [5.6%] vs 29 of 293 [9.9%]; adjusted RR, 0.54 [95% CI, 0.30-0.98]; P = .04). No significant difference was observed in mortality between groups (methylprednisolone, 92 of 284 [32.4%] vs placebo, 111 of 239 [37.9%]; adjusted RR, 0.84 [95% CI, 0.67-1.05]; P = .13).
CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial of intravenous methylprednisolone vs placebo for patients with intracranial ICA occlusion undergoing EVT, intravenous methylprednisolone was associated with improved ambulation. These findings suggest that the use of intravenous methylprednisolone as an adjunct to EVT may hold promise as a treatment option for patients with AIS due to intracranial ICA occlusion.
TRIAL REGISTRATION: ChiCTR.org.cn Identifier: ChiCTR2100051729.
参考来源
- Zheng C, Li R, Shen C, et al. Methylprednisolone as Adjunct to Thrombectomy for Acute Intracranial Internal Carotid Artery Occlusion Stroke: Post Hoc Secondary Analysis of the MARVEL Randomized Clinical Trial. JAMA Netw Open. 2025. PMID: 39964685. doi:10.1001/jamanetworkopen.2024.59945
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。